[ad_1] Citi is so bullish on one biotech firm that it has given its shares a target price that represents around 800% upside. That company is U.S.-listed Biomea Fusion , which develops covalent therapies to treat cancers and metabolic diseases. These therapies offer “a number of potential advantages over conventional non-covalent drugs including greater target…
[ad_1] One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition….
[ad_1] Zoetis shares have fallen about 10% since their recent peak in late July amid concerns that a weakening economy will prompt consumers to spend less on their pets. But investors may be overlooking the opportunity from a key product launch that could become one of the biggest in animal health history. A recent survey…
[ad_1] A safer, quicker way to treat some heart arrhythmia cases could be on the horizon, creating an opportunity for medical device companies Boston Scientific and Medtronic, according to Piper Sandler analyst Matt O’Brien. Atrial fibrillation (AF) is the most common type of heart arrhythmia, according to the Centers for Disease Control and Prevention. It…
